| Isolation of high affinity human antibodies directly from large synthetic repertoires. AD Griffiths, SC Williams, O Hartley, IM Tomlinson, P Waterhouse, ... The EMBO journal 13 (14), 3245-3260, 1994 | 1438 | 1994 |
| The making of bispecific antibodies U Brinkmann, RE Kontermann MAbs 9 (2), 182-212, 2017 | 811 | 2017 |
| Bispecific antibodies RE Kontermann, U Brinkmann Drug discovery today 20 (7), 838-847, 2015 | 645 | 2015 |
| Strategies for extended serum half-life of protein therapeutics RE Kontermann Current opinion in biotechnology 22 (6), 868-876, 2011 | 631 | 2011 |
| Dual targeting strategies with bispecific antibodies R Kontermann MAbs 4 (2), 182-197, 2012 | 554 | 2012 |
| Recombinant bispecific antibodies for cancer therapy RE Kontermann Acta Pharmacologica Sinica 26 (1), 1-9, 2005 | 346 | 2005 |
| Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin D Muller, A Karle, B Meissburger, I Hofig, R Stork, RE Kontermann Journal of biological chemistry 282 (17), 12650-12660, 2007 | 293 | 2007 |
| Strategies to extend plasma half-lives of recombinant antibodies RE Kontermann BioDrugs 23, 93-109, 2009 | 263 | 2009 |
| Recombinant single-chain Fv fragments carrying C-terminal cysteine residues: production of bivalent and biotinylated miniantibodies SM Kipriyanov, S Dübel, F Breitling, RE Kontermann, M Little Molecular immunology 31 (14), 1047-1058, 1994 | 224 | 1994 |
| Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen HH Heidtmann, DM Nettelbeck, A Mingels, R Jäger, HG Welker, ... British journal of cancer 81 (8), 1269-1273, 1999 | 195 | 1999 |
| Antibody Engineering Volume 2 R Kontermann, S Dübel springer, 2010 | 193 | 2010 |
| Half-life extended biotherapeutics RE Kontermann Expert opinion on biological therapy 16 (7), 903-915, 2016 | 191 | 2016 |
| Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105) DM Nettelbeck, DW Miller, V Jérôme, M Zuzarte, SJ Watkins, RE Hawkins, ... Molecular Therapy 3 (6), 882-891, 2001 | 191 | 2001 |
| Bispecific antibodies for cancer immunotherapy: Current perspectives D Müller, RE Kontermann BioDrugs 24, 89-98, 2010 | 188 | 2010 |
| Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors B Anliker, T Abel, S Kneissl, J Hlavaty, A Caputi, J Brynza, IC Schneider, ... Nature methods 7 (11), 929-935, 2010 | 184 | 2010 |
| Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells P Hölig, M Bach, T Völkel, T Nahde, S Hoffmann, R Müller, ... Protein Engineering Design and Selection 17 (5), 433-441, 2004 | 178 | 2004 |
| Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv) S Dübel, F Breitling, R Kontermann, T Schmidt, A Skerra, M Little Journal of immunological methods 178 (2), 201-209, 1995 | 170 | 1995 |
| A strategy of exon shuffling for making large peptide repertoires displayed on filamentous bacteriophage. I Fisch, RE Kontermann, R Finnern, O Hartley, AS Soler-Gonzalez, ... Proceedings of the National Academy of Sciences 93 (15), 7761-7766, 1996 | 169 | 1996 |
| Selective targeting of TNF receptors as a novel therapeutic approach R Fischer, RE Kontermann, K Pfizenmaier Frontiers in cell and developmental biology 8, 401, 2020 | 163 | 2020 |
| Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration Y Dong, R Fischer, PJW Naudé, O Maier, C Nyakas, M Duffey, ... Proceedings of the National Academy of Sciences 113 (43), 12304-12309, 2016 | 162 | 2016 |
Ulrich BrinkmannRocheGeverifieerd e-mailadres voor roche.com
